The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma

Blood

Volumn 117, Issue 13, 2011, Pages 3680-3683

  Chen, Junmei ^a   Hobbs, William E ^a,b   Le, Jennie ^a   Lenting, Peter J ^c,d   De Groot, Philip G ^c   López, José A ^a,b,e  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Dept Environ Med Natl Inst Publ HIth   (Norway)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONFORMATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HEMATOCRIT; HEMOLYSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; THROMBOCYTE COUNT;

EID: 79953716525     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-302539     Document Type: Article

References (24)

1. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326-328.
2. Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65(1):154-160. (Pubitemid 10214342)
3. Schwartz RS, Tanaka Y, Fidler IJ, et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J Clin Invest. 1985;75(6):1965-1972. (Pubitemid 15233585)
4. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285. (Pubitemid 43345545)
5. Chen J, López JA. Interactions of platelets with subendothelium and endothelium. Microcirculation. 2005;12(3):235-246. (Pubitemid 40691821)
6. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033-4039. (Pubitemid 35396870)
7. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977. (Pubitemid 35332036)
8. Mohandas N, Evans E. Sickle erythrocyte adherence to vascular endothelium: morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins. J Clin Invest. 1985;76(4):1605-1612. (Pubitemid 16193582)
9. Wick TM, Moake JL, Udden MM, et al. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest. 1987;80(3):905-910. (Pubitemid 18003966)
10. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood. 1993;81(9):2429-2438. (Pubitemid 23127081)
11. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662-1666.
12. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435. (Pubitemid 13234018)
13. Krishnan S, Siegel J, Pullen G Jr et al. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res. 2008;122(4):455-458.
14. Schnog JJ, Hovinga JA, Krieg S, et al.ADAMTS13 activity in sickle cell disease. Am J Hematol. 2006;81(7):492-498.
15. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor: a potential therapy for thrombotic thrombocytopenic purpura. J Clin Invest. 2011;121(2):593-603.
16. Hulstein JJ, de Groot PG, Silence K, et al. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106(9):3035-3042. (Pubitemid 41565896)
17. Wu JJ, Fujikawa K, Lian EC, et al.Arapid enzyme-linked assay for ADAMTS-13. J Thromb Haemost. 2006;4(1):129-136.
18. Groot E, de Groot PG, Fijnheer R, Lenting PJ. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007;14(3):284-289. (Pubitemid 46597616)
19. Groot E, Fijnheer R, Sebastian SA, de Groot PG, Lenting PJ. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost. 2009;7(6):962-969.
20. Mohan JS, Lip PL, Blann AD, Bareford D, Lip GY. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol. 2005;89(7):815-819. (Pubitemid 40904800)
21. Bolanos-Meade J, Keung YK, Lopez-Arvizu C, Florendo R, Cobos E. Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Ann Hematol. 1999;78(12):558-559. (Pubitemid 30009358)
22. Shelat SG. Thrombotic thrombocytopenic purpura and sickle cell crisis. Clin Appl Thromb Hemost. 2010;16(2):224-227.
23. Walmet PS, Eckman JR, Wick TM. Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions. Am J Hematol. 2003;73(4):215-224. (Pubitemid 36898876)
24. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115(3):706-712.